Immunotherapy Of Vestibular Function Impact

Overview

About this study

The purpose of this study is to determine if immunotherapy  checkpoint inhibitors influence vestibular function.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • At least 18 years of age at screening.

  • Patients who will be initiating single agent immunotherapy with pembrolizumab, cemiplimab, nivolumab, atezolizumab, or dual therapy with (Ipilimumab/Nivolumab or Nivolumab/Relatlimab).

Exclusion Criteria:

  • Concurrent chemotherapy.

Eligibility last updated 11/2/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Carrlene Donald, P.A.-C., M.S.

Contact us for the latest status

Contact information:

Carrlene Donald P.A.-C., M.S.

(480) 342-4200

donald.carrlene@mayo.edu

More information

Publications

Publications are currently not available